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http://dx.doi.org/10.1016/j.ccell.2015.07.005SUMMARYBy integrating growth pathways on which cancer cells rely, steroid receptor coactivators (SRC-1, SRC-2,
and SRC-3) represent emerging targets in cancer therapeutics. High-throughput screening for SRC small
molecule inhibitors (SMIs) uncovered MCB-613 as a potent SRC small molecule ‘‘stimulator’’ (SMS).
We demonstrate that MCB-613 can super-stimulate SRCs’ transcriptional activity. Further investigation
revealed that MCB-613 increases SRCs’ interactions with other coactivators and markedly induces ER
stress coupled to the generation of reactive oxygen species (ROS). Because cancer cells overexpress
SRCs and rely on them for growth, we show that we can exploit MCB-613 to selectively induce excessive
stress in cancer cells. This suggests that over-stimulating the SRC oncogenic program can be an effective
strategy to kill cancer cells.INTRODUCTION
Members of the p160 steroid receptor coactivator (SRC)
family, SRC-1/NCOA1, SRC-2/NCOA2/TIF2/GRIP1 and SRC-3/
NCOA3/AIB1/RAC3/ACTR/pCIP interact with nuclear receptors
and other transcription factors to drive target gene expression
while also functioning as integrators of upstream cell signaling
pathways (Lonard and O’malley, 2007). Although they share
homology with each other, they have distinct and important
roles in multiple physiological processes, including growth and
development, reproduction, and metabolism (Xu et al., 2009;
York and O’Malley, 2010). All three proteins have also been
found to be broadly involved in different aspects of tumorigen-
esis. SRC-3 is best known for its oncogenic role, and its gene
is amplified in 9.5% of breast cancers (Anzick et al., 1997), and
its mRNA has been shown to be overexpressed in different
breast cancer cohorts, often at the 50% level or greater (AnzickSignificance
Because of their essential roles in tumorigenesis, SRC family c
gets for future cancer therapeutics. Because SRC proteins inte
achieve accelerated growth, invasion, energy metabolism, an
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2003). Clinically, SRC-3 overexpression in breast cancer corre-
lates with larger tumor size (Bautista et al., 1998), higher tumor
grade (Hudelist et al., 2003) and poor survival rates (Zhao
et al., 2003). Direct evidence supporting SRC-3 as a bona fide
oncogene comes from an MMTV-SRC-3 transgenic mouse
model in which overexpression of SRC-3was sufficient to cause
the spontaneous development of malignant mammary tumors
(Torres-Arzayus et al., 2004). SRC-3 overexpression has also
been observed in endometrial (Kershah et al., 2004), ovarian
(Bautista et al., 1998), prostate (Gnanapragasam et al., 2001),
colorectal (Xie et al., 2005), gastric (Sakakura et al., 2000), lung
(Cai et al., 2010), pancreatic (Henke et al., 2004), and liver can-
cers (Wang et al., 2002). Additional in vitro and in vivo studies
have bolstered the importance of SRC-3 in tumor initiation,
progression, metastasis, and drug resistance (Xu et al., 2009).
SRC-1 is also overexpressed in about 20% of breast cancersoactivators have been recognized recently as important tar-
grate and drive key oncogenic pathways cancer cells use to
d metastasis, SRC SMIs/SMSs are expected to be effective
described, here we report the characterization of an SRC
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ess response pathways are already maximally engaged.
and is positively correlated with ERBB2 expression, disease
recurrence, and poor survival (Fleming et al., 2004; Myers
et al., 2004). It has been demonstrated that SRC-1 plays a critical
role in cancer cell migration, invasion, and metastasis (Qin et al.,
2009). Finally, SRC-2 has been proposed as a key oncogene in
prostate cancer based on a comprehensive analysis of prostate
tumors, cell lines, and xenografts, revealing that SRC-2 gene
amplification, overexpression, and mutations specifically arise
to levels of 38% in metastatic prostate tumors (Taylor et al.,
2010).
Although tumor formation is a multistage process involving the
activation of oncogenes and inactivation of tumor suppressors,
accumulating evidence indicates that loss of a specific onco-
gene can frequently reverse the malignant progression of cancer
cells, suggesting that cancer cells rely on the continued activa-
tion or overexpression of an oncogene (Chin et al., 1999; Felsher
and Bishop, 1999; Huettner et al., 2000). This ‘‘oncogene addic-
tion’’ theory, combined with the fact that SRC proteins integrate
and promote multiple growth factor signaling pathways crucial
for cancer cell growth and survival (Fereshteh et al., 2008;
Torres-Arzayus et al., 2004, 2006), highlights the potential value
of SRC-targeting drugs as future anti-cancer agents. In an initial
proof-of-principle study, we identified gossypol as a small mole-
cule inhibitor (SMI) of SRC-1 and SRC-3 that can decrease the
SRC-1/3 protein level and cause cell death in various cancer
cell lines (Wang et al., 2011). Inspired by this result, a large
high-throughput compound screening campaign was under-
taken against all three SRCs, leading to the identification of
improved SRC SMIs, including bufalin and verrucarin A (Wang
et al., 2014; Yan et al., 2014).
Because cancer cells rely heavily on SRCs tomaintain homeo-
stasis, we further hypothesized that the over-stimulation of SRCs
through small molecule stimulators, although mechanistically
distinct from that of SRC SMIs, might also be able to disrupt
the borderline homeostasis of cancer cells, leading to acute
stress enhancement and cell death, especially in cancer cells
that depend upon SRCs. In this study, we characterize an SRC
small molecule stimulator and investigate its biological activities
and anti-cancer potential.
RESULTS
MCB-613 Is a Pan-SRC Stimulator
In a series of high-throughput screens originally designed to
identify SRC SMIs, HEK293 cells transfected with a Gal4-
responsive luciferase reporter (pG5-luc) and a construct encod-
ing SRC-1, SRC-2, or SRC-3 fused with the DNA binding domain
of Gal4 (pBIND-SRC-1, pBIND-SRC-2, or pBIND-SRC-3) were
exposed to treatment with 359,484 compounds from a Molecu-
lar Libraries Probe Production Centers Network (MLPCN) chem-
ical library (PubChem AID: 588362, 652008, 588354). In addition
to the inhibitors that were initially sought in these screens, a num-
ber of compounds were found to stimulate the activity of SRC-1
and SRC-3. Primary screens indicated that there were 106
and 28 potential SRC-1 and SRC-3 stimulators, respectively,
using a 2-fold activation cutoff compared with vehicle controls.
Upon further testing and verification, MCB-613 (4-ethyl-2,6-
bis-pyridin-3-ylmethylene-cyclohexanone) (Figure S1A), which
exerted the greatest activation of SRC-1 in the primary screen,was confirmed to be a strong activator of all three SRCs. As
shown in Figure 1A, 24-hr treatment with MCB-613 caused an
extremely large and unprecedented (maximum 160-fold) induc-
tion in the activity of pBIND-SRC-1/2/3 in a dose-dependent
manner. This stimulation by MCB-613 was selective for SRCs,
failing to stimulate a GAL4-PGC-1a coactivator fusion protein
(Figure 1B) while minimally increasing the activity of GAL4-
VP16 only at higher compound concentrations (Figure S1B).
The activation of SRCs by MCB-613 was so strong and rapid
that a significant increase in SRC activity was already observed
after 4 hr of treatment (Figure S1E), and it represents the stron-
gest stimulation observed to date under any conditions.
Because SRC-3 has been shown to be preferentially utilized
by AP-1 and PEA3 as a coactivator to drive the expression of
MMP2 and MMP13 (Yan et al., 2008), we transfected cells with
a MMP2 or MMP13 promoter-driven luciferase reporter
(MMP2-luc or MMP13-luc) and treated these cells with MCB-
613. We found that SRC-3’s coactivation of these promoters
was greatly enhanced by MCB-613 (Figure 1C). To confirm
that the MCB-613 effect is SRC-dependent, we performed the
same experiment in an SRC-3 knockout (KO) HeLa cell line in
which both alleles of SRC-3 were knocked out using a zinc
finger nuclease (Wang et al., 2014) and found that activation of
MMP2-luc by MCB-613 was diminished (Figure 1D). As a further
validation, knocking down all three SRCs together with small
interfering RNAs (siRNAs) significantly impaired the ability of
MCB-613 to activate theMMP2 promoter (Figure S1C). Consis-
tent with these findings, endogenous MMP13 expression could
be also activated with MCB-613 treatment (Figure 1E).
To characterize the underlying mechanism of MCB-613’s
activation of SRCs, we initially sought to determine whether
MCB-613 increases SRC activity by elevating the concentrations
of SRC proteins in the cell. Instead, we found that treatment
with MCB-613 resulted in decreases in SRC-1, SRC-2, and
SRC-3 protein levels (Figure 1F), indicating that MCB-613 inher-
ently promotes the intrinsic activity of SRCs. The reduction of
SRC proteins is not a transcriptional event because the mRNA
levels of SRC-1/2/3 were not downregulated by MCB-613
treatment (Figure S1D). It has been demonstrated previously
by our laboratory that SRC-3 activation is coupled to its turnover
(Wu et al., 2007). Therefore, the increased SRC protein insta-
bility/degradation is probably associated with their hyper-activa-
tion. Our time course experiment also supports the idea that
there is a correlation between SRC-3’s activity and protein level
under the treatment of MCB-613. As shown in Figure S1E, 4 hr
was the earliest time point when we could see the activation of
SRC-3 by MCB-613 in luciferase assays, and it is at this time
point that we started to observe a significant decrease in
SRC-3 protein level.
Next we assessed whether MCB-613 physically interacts with
SRCs by using the technique of surface plasmon resonance
(SPR) (Karlsson and Sta˚hlberg, 1995). A series of concentrations
of MCB-613 were flowed over immobilized SRC-3 protein frag-
ments, including the receptor-interacting domain (RID), CBP-
interacting domain (CID), and the basic helix-loop-helix (bHLH)
domain, with an increase in the SPR signal indicating direct
binding. As shown in Figure 1G, MCB-613 binds to the RID of
SRC-3 in a reversible manner; the SPR signal subsided when
MCB-613 was removed. The same interaction was confirmedCancer Cell 28, 240–252, August 10, 2015 ª2015 Elsevier Inc. 241
AC
D
G H
E
F
B
Figure 1. MCB-613 Selectively Activates the Intrinsic Transcriptional Activity of SRCs
(A) Luciferase assays onHeLa cells co-transfected with the pG5-luc and pBIND or pBIND-SRC-1/2/3 expression vectors after the treatment ofMCB-613 for 24 hr.
RLU, relative light unit.
(B) Luciferase assays on HeLa cells co-transfected with the pG5-luc and Gal4-DBD or Gal4-PGC-1a expression vectors and treated with increasing concen-
trations of MCB-613 for 24 hr.
(C) Luciferase assays on HeLa cells co-transfected with an SRC-3 expression vector and the MMP2-luc or MMP13-luc reporter and treated with MCB-613 for
24 hr.
(D) Luciferase assays on SRC-3 WT or KO HeLa cells transfected with a MMP2-luc reporter plasmid and treated with MCB-613 for 24 hr.
(E) qRT-PCR analysis of MMP13 in MDA-MB-231 cells treated with MCB-613 for 24 hr.
(F) Immunoblotting of SRCs from HeLa cells treated with MCB-613 for 24 hr.
(legend continued on next page)
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by fluorescence spectroscopy, which measured the intrinsic
fluorescence of different SRC-3 protein domains in the presence
of MCB-613 based on the theory that direct SRC-3 binding with
MCB-613 should quench its intrinsic fluorescence emission
(Epps et al., 1999; Wang et al., 2011). As shown in Figure S1F,
the intrinsic fluorescence of the RIDwas progressively quenched
by increasing concentrations of MCB-613, and the emission
maximum was shifted from 340 to 360 nm, again indicating
that MCB-613 binds directly to the SRC-3 RID. Both of these
two assays showed that a much higher concentration of MCB-
613 is required for the interaction between SRC-3 CID and
MCB-613, and, because of noisy data, a clear conclusion about
the bHLH domain of SRC-3 could not be reached (data not
shown). Taken together, these results suggest that MCB-613
selectively and reversibly binds to the RID of SRC-3.
Activated SRC-3 has been shown to recruit other transcrip-
tional coactivators, including CBP and CARM1, to form a
multi-coactivator complex (Chen et al., 1997, 1999; Foulds
et al., 2013). To test whether MCB-613 affects the ability of
SRC-3 to interact with these coactivator complex members,
HeLa cells overexpressing FLAG-SRC-3 were treated with
MCB-613 for 1 hr and subjected to coimmunoprecipitation to
assess SRC-3-CBP-CARM1 complex formation. As shown in
Figure 1H, MCB-613 increased SRC-3’s interaction with CBP
and CARM1 robustly in a dose-dependent manner. Longer treat-
ment of 4 or 8 hr with the compound increased the SRC-3-CBP
interaction, whereas no further interaction between SRC-3 and
CARM1 was observed (Figures S1G and S1H). These results
indicate that MCB-613 binds to SRC-3, where it then promotes
coactivator complex formation, consistent with induced coacti-
vator transcriptional activity.
MCB-613 Selectively Kills Cancer Cells
While studying the activation of SRCs by MCB-613, we noticed
thatMCB-613 is cytotoxic. It can efficiently kill a variety of human
cancer cell lines (Figure 2A), including MCF-7 (breast), PC-3
(prostate), H1299 (lung), and HepG2 (liver) cells. Intriguingly,
although highly toxic to cancer cells, MCB-613 can spare normal
cells at these concentrations, because mouse primary hepato-
cytes and mouse embryonic fibroblasts (MEFs) are resistant to
this compound (Figure 2A). To rule out the possible species-
specific toxicity of MCB-613, we tested the compound on
primary human umbilical vein endothelial cells (HUVECs) and
found that, at low concentrations of MCB-613, HUVECs are
more resistant than almost all human cancer cell lines we tested
(Figure S2A), although cell death still occurs at high doses of the
compound, which, in part, may be due to the higher fragility of
primary human cells in culture.
One prominent phenomenon we observed is that MCB-613
treatment induced massive cytoplasmic vacuolization (Fig-
ure 2B). To better understand how MCB-613 causes cell death,
we first examined whether apoptosis or autophagy was acti-(G) SPR showing the direct binding of MCB-613 to the SRC-3 RID. Top: SPR sign
Bottom: the RID’s SPR signals normalized against a reference cell with no immobil
unit.
(H) Immunoblotting of CBP and CARM1 in the coimmunoprecipitation (co-IP) c
MCB-613 at the indicated concentrations for 1 hr.
Data are presented as mean ± SEM. **p < 0.01, ***p < 0.001. See also Figure S1vated, especially considering that autophagy is the major cell
death mechanism linked to vacuolization. MCB-613 treatment
led to the induction of LC3BII and caspase-3 cleavage, markers
for autophagy and apoptosis, respectively (Figure S2B). How-
ever, autophagy inhibitors such as chloroquine and 3-methyla-
denine (3-MA) cannot rescue cell death caused by MCB-613
(Figure S2C), suggesting that autophagy is not involved in cyto-
toxicity and that it is probably induced by the cells as a futile
survival response. Although a caspase inhibitor, z-VAD-fmk,
can inhibit MCB-613-mediated cell death to a significant extent
(Figure S2C), MCB-613, unlike other known apoptosis inducers
such as etoposide and sodium nitroprusside (SNP), does not
cause inter-nucleosomal DNA fragmentation, a classic nuclear
characteristic of apoptosis (Figure S2E), implying that apoptosis
might not be the primary form of cell death. In addition, neither
apoptosis nor autophagy was directly linked to the activation
of SRCs because z-VAD-fmk, chloroquine, or 3-MA did not
inhibit the activation of SRC-3 by MCB-613 (Figure S2D).
A non-apoptotic form of cell death, paraptosis, is character-
ized by extensive cytoplasmic vacuolization caused by the dila-
tion of ER and mitochondria, and it does not rely upon hallmarks
of apoptosis such as DNA fragmentation and caspase activation
(Sperandio et al., 2000). Paraptotic-like cell death has been
observed in embryo development (Clarke, 1990) and neuronal
degeneration (Pilar and Landmesser, 1976), in several artificial
or natural cellular models (Abraham et al., 2007; Chen et al.,
2002; Sperandio et al., 2000), and in response to treatment
with some anti-cancer agents (Kar et al., 2009; Yoon et al.,
2010). Although the molecular details underlying paraptosis are
still relatively understudied, there is evidence suggesting that
the vacuolization results from perturbations in ER and protea-
some functions (Denoyelle et al., 2006; Mimnaugh et al., 2006;
Ustundag et al., 2007). In addition to proteasome dysfunction
and ER stress, paraptosis requires de novo protein synthesis
and is linked to cellular redox homeostasis (Sperandio et al.,
2000; Yoon et al., 2010).
Intrigued by the possibility that paraptosis might be involved in
MCB-613’s effect, we used transmission electron microscopy
(TEM) to examine in detail the morphology and ultrastructure
of the cells after the treatment with the compound. As shown
in Figure S2F, compared with vehicle-treated cells, which have
normal mitochondria and ER, cells treated with MCB-613 for
8 hr have vacuoles of various sizes throughout their cytoplasm,
consistent with paraptosis. In addition, these cells show no
signs of chromatin condensation, nuclear fragmentation, or
cellular blebbing, again suggesting that they are not going
primarily through apoptosis. Moreover, those vacuoles show
no resemblance to autophagosomes, which are double-
membraned vesicles usually containing proteins or organelles
destined for degradation. However, we do see autophagosomes
in MCB-613-treated cells by TEM (data not shown), which is in
agreement with the induction of LC3BII. To further investigateal traces of the RID in the presence of increasing concentrations of MCB-613.
ized protein exposed to increasing concentrations of MCB-613. RU, resonance
omplex from FLAG or FLAG-SRC-3-overexpressing HeLa cells treated with
.
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Figure 2. MCB-613 Induces Complex Cytotoxicity with Characteristics of Paraptotic-like Cell Death
(A) Viability of the indicated cells treated with MCB-613 for 48 hr.
(B) Extensive cytoplasmic vacuolization in the indicated cancer cell lines treated with MCB-613. Scale bars, 20 mm.
(C) Immunofluorescence of calnexin in HeLa cells treated with MCB-613 for 24 hr. Scale bars, 20 mm. DAPI, 40,6-diamidino-2-phenylindole.
(D) ROS levels in MCB-613-treated HeLa cells as demonstrated by CM-H2DCFDA, a general ROS indicator. Scale bars, 20 mm.
(E) Immunoblotting of ubiquitin from HeLa cells treated with MCB-613 for 5 hr.
(legend continued on next page)
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whether the cytotoxicity induced by MCB-613 exhibits para-
ptotic features, we confirmed the ER origin of the MCB-613-
induced vacuoles because they stained positive for calnexin
(Figure 2C), an ER-specific marker. Next, by using CM-
H2DCFDA, a general reactive oxygen species (ROS) indicator,
we found that MCB-613 can induce a rapid andmarked increase
in intracellular ROS levels (Figure 2D). MCB-613 also leads to
proteasome dysfunction and ER stress, as confirmed by the
accumulation of polyubiquitinated proteins (Figure 2E) and the
induction of the markers for unfolded protein response (UPR)
(Figure 2F), including the phosphorylation of eIF2a (EIF2A)
and IRE1a (ERN1) as well as the induction of ATF4 protein
expression. Because MCB-613 increases ROS levels and
paraptosis requires protein synthesis, we next examined
whether an antioxidant or a protein synthesis inhibitor can block
cell death caused by MCB-613. As shown in Figure 2G, the
antioxidant N-acetyl cysteine (NAC) and the protein synthesis
inhibitor cycloheximide (CHX) protected cells from MCB-613-
mediated cytotoxicity. We further confirmed that NAC can
efficiently eradicate the high level of ROS in the cells treated
with MCB-613 (Figure S2G). Consistently, another antioxidant,
Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP), a
superoxide dismutase (SOD) mimetic, can retard MCB-613-
induced cell death, although not as effectively as NAC (Fig-
ure S2H). Importantly, vacuolization induced by MCB-613 was
also blocked by co-treatment with NAC or CHX (Figure 2H),
pointing to paraptotic-like cell death as the primary process
underlying the cytotoxic properties of MCB-613. Taken together,
these results indicate that MCB-613 selectively kills cancer cells
by inducing complex cytotoxicity with features that are charac-
teristic of paraptosis. The apoptotic effect, we speculate, might
be a secondary response to higher concentrations or longer
treatment time with MCB-613.
SRC Hyper-activation Is Critical for the Paraptotic
Cytotoxicity Induced by MCB-613
One key to understanding the mechanism of MCB-613 is to
establish the order of events regarding whether SRC activation
is a consequence of UPR induction or vice versa. We found
that known ER stress inducers such as tunicamycin failed
to recapitulate the effect of MCB-613 to hyper-activate SRC-3
(Figure S3A). In addition, although MCB-613 seems to share
some structural similarity with a recently identified activator of
eukaryotic translation initiation factor 2-a kinase 3 (PERK,
EIF2AK3) (Bai et al., 2013), its ability to induce the splicing of
XBP1, another marker of UPR, remains intact in the absence
of PERK expression (Figure S3B). Importantly, activation of
SRC-3 byMCB-613 is not impacted when essential UPR players
like PERK or IRE1a are knocked down by siRNA (Figures S3C
and S3D). All of these data strongly support the notion that
MCB-613 is distinct from other UPR inducers and that SRC
hyper-activation by MCB-613 does not rely on but, instead, pre-
cedes UPR induction. We proceeded to determine whether a(F) Immunoblotting of the indicated UPR markers from HeLa cells treated with M
(G) Viability of HeLa cells treated with MCB-613 for 24 hr in the presence or abs
(H) Morphology of HeLa cells treated as in (G). Scale bars, 40 mm.
Data are presented as mean ± SD. ***p < 0.001. See also Figure S2.causal link exists between SRC super-activation by MCB-613
and paraptotic-like cell death. SRC-3 KO HeLa cell viability
was found to be less affected by MCB-613 compared with
wild-type (WT) cells (Figure 3A), suggesting that the cell death
induced by MCB-613 is at least partially dependent on SRC-3
(SRC-1 and SRC-2 are still expressed in SRC-3 KO cells). We
next sought to examine the expression of downstream stress
response genes that are induced by MCB-613 in a SRC-3-
dependent manner using the human stress and toxicity
PathwayFinder qPCR array on SRC-3 WT or KO HeLa cells
treated with MCB-613. The array focuses on genes involved in
oxidative stress, hypoxia, DNA damage, and UPR. As shown in
Figure 3B, multiple UPR regulators or downstream targets
such as ATF6B, CHOP, DNAJC3, and TNFRSF10B were either
downregulated or upregulated significantly upon MCB-613
treatment in WT cells. However, these changes were all blunted
in SRC-3 KO cells, again suggesting that SRC-3 stimulation
partly underlies the stress response pathways activated by
MCB-613 treatment.
We also found that oxidative stress-related genes are differen-
tially regulated in MCB-613-treated SRC-3 WT and KO cells
(Figure 3C). Lactate dehydrogenase A (LDHA) is an enzyme
that converts L-lactate and nicotinamide adenine dinucleotide
(NAD+) to pyruvate and NADH in the final step of anaerobic
glycolysis, whose inhibition has been shown to increase oxida-
tive stress and interfere with tumor progression (Le et al.,
2010). Glutathione reductase (GSR) is a central enzyme respon-
sible for cellular antioxidant defense. MCB-613 treatment re-
sulted in decreased LDHA expression and an increase in GSR
expression in WT HeLa cells, consistent with the notion that
the cells are attempting to mount a response to the ROS-
generating effects of MCB-613. Meanwhile, in SRC-3 KO cells
treated with MCB-613, there was an attenuated decrease in
LDHA expression and a stronger increase in GSR expression
compared with WT cells, implying that the KO cells are more
resistant toMCB-613 and suffered less oxidative stress because
of the absence of SRC-3.
As a further demonstration that SRC activation drives
the paraptotic-like cytotoxicity of MCB-613, siRNA-mediated
knockdown of all three SRCs simultaneously led to a significant
impairment of both the splicing of XBP1 and the induction of
ATF4 caused by MCB-613 treatment (Figure 3D; Figure S3E).
Along the same lines, cytoplasmic vacuolization and the induc-
tion of ATF4 were effectively inhibited by the co-treatment of
MCB-613 with the SRC SMI bufalin (Figures 3E and 3F), which
has been shown to inhibit all three SRCs (Wang et al., 2014).
Instead, bufalin treatment induced caspase-3 cleavage (Fig-
ure 3F), consistent with prior findings that loss of SRC-3 can
lead to apoptosis (List et al., 2001). Together, thesemultiple lines
of evidence lay a strong foundation supporting that the UPR
induction byMCB-613 is SRC-dependent and that hyper-activa-
tion of SRCs is responsible for the paraptotic-like cell death
response induced by this compound.CB-613 for 4 hr.
ence of NAC or CHX.
Cancer Cell 28, 240–252, August 10, 2015 ª2015 Elsevier Inc. 245
AB
C
E
F
D
Figure 3. SRC Hyper-activation Is Critical for the Paraptotic-like Cytotoxicity Induced by MCB-613
(A) Viability of SRC-3 WT or KO HeLa cells treated with MCB-613 for 24 hr.
(B) qRT-PCR analysis of the indicated UPR factors in SRC-3 WT and KO HeLa cells treated with MCB-613 for 24 hr.
(C) qRT-PCR analysis of LDHA and GSR from SRC-3 WT and KO HeLa cells treated as in (B).
(D) Immunoblotting of spliced XBP1 and SRCs from HeLa cells transfected with control siRNAs or siRNAs targeting all three SRCs and treated with MCB-613 for
24 hr. The numbers indicate the quantification of the bands for spliced XBP1.
(E) Morphology of HeLa cells treated with MCB-613 for 24 hr in the presence or absence of bufalin. Scale bars, 40 mm. EtOH, ethanol.
(F) Immunoblotting of ATF4, cleaved caspase-3, and SRCs from HeLa cells treated as in (E). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Data are presented as mean ± SD (cell viability assay) or mean ± SEM (qRT-PCR). **p < 0.01, ***p < 0.001. See also Figure S3.
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One response in which cells engage to counteract ER stress is
to induce molecular chaperones such as heat shock proteins to
enhance the folding capacity of the ER and alleviate the accumu-
lation of misfolded/unfolded proteins. Indeed, many heat shock
proteins were significantly induced by treatment with MCB-613
(Figure S3F), suggesting that the cells are striving to battle the
enormous stress imposed by the compound. Based on this
observation, we speculated that, if excessive ER stress is the pri-
mary cause of cell death induced by MCB-613, then inhibiting
heat shock protein function should further aggravate the delete-
rious effect of this compound. As expected, geldanamycin, an
HSP90 inhibitor, synergizes with MCB-613 to induce ER stress
and enhances MCB-613-mediated cell death (Figures S3G and
S3H). Consistently, knocking down HSF1 (heat shock factor 1),
a major transcription factor for heat shock proteins, also exacer-
bates the cell death caused by MCB-613 (Figure S3I). Interest-
ingly, the synergism between MCB-613 and geldanamycin also
applied to the activation of SRC-3 (Figure S3J), further implying
that super-activation of SRCs is integral to the effect ofMCB-613
on ER stress and cell viability.
More support for the close relationship between SRCs and
paraptotic-like cell death is evidenced by our observations
that additional agents, including curcumin, 15-deoxy-D12,14-
prostaglandin J2 (15d-PGJ2), andMG132, can robustly enhance
the intrinsic transcriptional activities of SRCs (Figures S3K
and S3L). All of these agents have been shown to cause cell
death with cytoplasmic vacuolization and devastating stress
responses (Ding et al., 2007; Kar et al., 2009; Yoon et al.,
2010), suggesting that SRC hyper-stimulation is closely coupled
to cellular stress pathways connected to paraptosis.
Oxidative Stress Induced by MCB-613 Is SRC-
Dependent and Contributes to SRC Hyper-activation
The rapid increase of intracellular ROS levels in response to
MCB-613 treatment led us to examine the relationship between
oxidative stress and the activation of SRCs.We found that simul-
taneous knockdown of all three SRCs significantly inhibits the
production of ROS by MCB-613 (Figure 4A), suggesting that
SRCs are indispensable for MCB-613-induced oxidative stress.
Interestingly, co-treatment with the antioxidant NAC was able
to abrogate the stimulatory effects of MCB-613 on SRC tran-
scriptional activity (Figure 4B; Figure S4A). At the same time,
the decrease of SRC protein levels normally seen in MCB-613
treated cells was blocked by NAC (Figure S4B), which, again,
confirms that there is a correlation between SRC activity and
protein level.
ROS have been shown to activate multiple kinase signaling
pathways (Ray et al., 2012), and, because SRCs are phospho-
proteins that function as conduits for growth factor kinase
cascades (Wu et al., 2004), we wanted to explore the impact of
MCB-613 treatment on SRC-3 phosphorylation. Using a phos-
tag SDS-PAGE system that allows phosphorylated proteins to
be characterized by differences in theirmigration rates (Kinoshita
et al., 2004), we found that MCB-613 treatment resulted in an
SRC-3 species with reduced mobility in the gel (Figure 4C) that
disappeared after l phosphatase treatment (data not shown),
indicative of a phosphorylated form of SRC-3. To investigate
which kinase(s) are responsible for MCB-613-induced phos-
phorylation, we screened a kinase inhibitor library from SelleckChemicals that contained a collection of 141 kinase inhibitors
and found that a number of Abl kinase inhibitors were able to
inhibit the activation of pBIND-SRC-3 by MCB-613 (Figure 4F;
data not shown).
Abl is a non-receptor tyrosine kinase present in both the cyto-
plasm and nucleus that has been implicated in a variety of
cellular processes such as growth, differentiation, and stress
response (Greuber et al., 2013). Consequently, Abl is a promising
candidate kinase involved in MCB-613-mediated SRC hyper-
stimulation because acute hyper-activation of the oncogenic
Bcr-Abl fusion protein has been shown to induce severe cyto-
plasmic vacuolization and ER stress (Dengler et al., 2011),
Abl has been shown to phosphorylate and activate SRC-3
(Oh et al., 2008), and Abl is activated in response to oxidative
stress (Sun et al., 2000). We first tested whether Abl is activated
by MCB-613 treatment by assaying CRKL (Y207) phosphoryla-
tion as a marker for Abl activation (de Jong et al., 1997). As
shown in Figure 4D, activation of Abl could be observed as early
as 1 hr after MCB-613 treatment and reached a high level after
4 hr of treatment. Moreover, CRKL phosphorylation caused by
MCB-613 is significantly attenuated in the presence of NAC (Fig-
ure S4C), further proving that Abl activation is dependent on
ROS induced by MCB-613. Subsequent co-immunoprecipita-
tion analysis revealed that MCB-613 increases the interaction
between SRC-3 and Abl (Figure 4E). Two Abl kinase inhibitors,
AT9283 and PHA739358, as well as siRNAs targeting Abl signif-
icantly inhibited the activation of SRC-3 by MCB-613 (Figures 4F
and 4G), confirming that oxidative stress induced by MCB-613
contributes to SRC activation via the Abl kinase signaling
pathway.
To better understand the phosphorylation pattern of SRC-3
induced by MCB-613 treatment, we generated pBIND-SRC-3
constructs with mutations to some of its known phosphorylation
sites, including S505, S543, and S857 (Wu et al., 2004), as well as
Y1357, which has been shown to be targeted by Abl (Oh et al.,
2008), and tested them alongside the WT pBIND-SRC-3. As
shown in Figure S4D, all of these mutants were hyper-activated
by MCB-613 in a similar fashion as the WT. Because mutating
these sites one by one cannot abrogate the effect of MCB-613,
this result suggests that MCB-613 treatment either induces
phosphorylation on more than one of these known sites or in-
duces phosphorylation on novel sites.
Despite its necessity in the activation process of SRCs by
MCB-613, an elevated ROS level alone is not sufficient to
achieve a robust stimulatory effect on SRCs because the ROS
inducer H2O2 cannot hyper-activate SRCs even though it is
capable of activating Abl kinase (Figures S4E and S4F). This
result also implies that, although Abl contributes to SRC hyper-
stimulation, it is not a driver of this phenomenon.
MCB-613 Inhibits Tumor Growth In Vivo
To further evaluate the anti-cancer potential of MCB-613, an
MCF-7 breast cancer mouse xenograft model was employed
to assess the tumor-suppressive effects of MCB-613 in vivo.
Tumors were established in athymic nude mice by injecting
MCF-7 cells into mammary fat pads. An MCB-613-treated
group (n = 13) received an intraperitoneal (i.p.) injection of the
compound (20 mg/kg) three times a week for 7 weeks, whereas
a control group (n = 14) was injected with a saline vehicle. AsCancer Cell 28, 240–252, August 10, 2015 ª2015 Elsevier Inc. 247
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Figure 4. Oxidative Stress Induced by MCB-613 Depends on SRCs and Drives Further SRC Hyper-activation via the Abl Kinase Signaling
Pathway
(A) ROS levels as indicated by CM-H2DCFDA in HeLa cells transfected with control siRNAs or siRNAs targeting all three SRCs and treated with MCB-613.
A representative picture from multiple fields is shown for each treatment (left). Fluorescence signals are quantified (center), and knockdown efficiency is shown
by immunoblotting (right). Scale bars, 200 mm.
(B) Luciferase assays on HeLa cells co-transfected with the pG5-luc and pBIND or pBIND-SRC-3 expression vectors and treated with increasing concentrations
of MCB-613 for 24 hr in the presence or absence of NAC.
(C) The immunoprecipitate from FLAG- or FLAG-SRC-3-overexpressing HeLa cells treated with MCB-613 at the indicated concentrations for 1 hr was resolved
on a 5% SDS-PAGE gel containing 20 mM phos-tag and immunoblotted with anti-FLAG antibody.
(D) Immunoblotting of phosphorylated CRKL from HeLa cells treated with MCB-613 for 1 or 4 hr.
(E) Immunoblotting of Abl in the co-IP complex from FLAG- or FLAG-SRC-3-overexpressing HeLa cells treated with MCB-613 at the indicated concentrations
for 1 hr.
(legend continued on next page)
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Figure 5. MCB-613 Inhibits Tumor Growth in an MCF-7 Xenograft
Model
(A) Tumor volume measurements of mice treated with vehicle (n = 14) or
MCB-613 (n = 13) for 7 weeks after tumor initiation. Data are presented as
mean ± SEM. *p < 0.05, **p < 0.01.
(B) Body weights of vehicle- or MCB-613-treated mice throughout the
treatment.shown in Figure 5A, MCB-613 significantly and dramatically
stalled the growth of the tumor compared with the control group
while causing no obvious animal toxicity; the body weights of
the control and treated groups were not statistically different
(Figure 5B).DISCUSSION
Despite the key roles of SRCs in a broad range of biological pro-
cesses pertinent to cancer cells, they have been considered by
many as potentially undruggable targets in cancer therapeutics
because of the lack of a structurally defined enzymatic activation
domain or a high-affinity ligand binding domain. However, our
recent identification of gossypol as an SRC-1/SRC-3 inhibitor
(Wang et al., 2011) established the proof of concept that it(F) Luciferase assays on HeLa cells co-transfected with pG5-luc and pBIND or pB
AT9283 or PHA739358.
(G) HeLa cells transfected with control siRNA or siAbl1 were transfected with
concentrations of MCB-613 for 24 hr and luciferase assays. The knockdown effi
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See alsois possible to target these coactivators with small molecule
compounds.
Compared with SRC inhibitors, using SRC stimulators in
cancer therapy initially appears counterintuitive given the onco-
genic actions of SRCs. However, even cancer cells that overex-
press SRCs need to delicately orchestrate a wide range of
cellular events to execute accelerated SRC-mediated cell prolif-
eration. The demands placed on cancer cells to cope with cell
stress are even more acute than normal cells because they are
already forced to deal with much higher rates of protein synthe-
sis/folding and elevated ROS levels (Grek and Tew, 2010).
We posit that elevated SRC activity beyond the already high
levels present in cancer cells can further pressure their already
maximized stress response system and selectively kill them.
In fact, we have noted repeatedly that cancer cells overexpress-
ing SRCs cannot be induced to further express increased SRC
levels without deleterious effects. Consistent with this phenom-
enon, forced overexpression of oncoproteins such as c-Myc has
been shown to cause cell death under certain conditions (Meyer
and Penn, 2008), although the mechanisms involved may be
distinct from what we observe due to SRC hyper-activation.
A mechanistic model is proposed in Figure 6 to delineate the
actions of MCB-613 on SRCs. By directly binding to SRCs,
MCB-613 dramatically activates these coactivators and pro-
motes the formation of a coactivator complex with SRC, CBP,
and CARM1. Meanwhile, the resultant rapid elevation of intra-
cellular ROS activates kinases such as Abl. These two events
work in concert to further hyper-activate SRCs. The deregula-
tion of cellular functions and homeostasis downstream of
SRCs leads to severe ER stress and UPR, processes known
to produce more ROS. Ultimately, this forms a destructive pos-
itive feedback loop that overwhelms the cancer cell, resulting in
vacuolization and cell death. It is known that, depending on
the cellular microenvironment and the nature of the stress, the
ER stress-induced UPR program can be either cytoprotective
or cytotoxic (Wang and Kaufman, 2012). Excessive ER stress
has been proposed as the cause of aberrant vacuolization
(Mimnaugh et al., 2006), and our data point to SRC hyper-stim-
ulation as playing a key role in triggering the ER stress that
drives this phenomenon. We recognize that dramatic increase
in ROS levels will result in profound changes in a broad spec-
trum of cellular processes. For instance, it has been published
recently that ROS induced by the metabolic switch in cancer
cells treated with a peroxisome proliferator-activated receptor
g (PPARg) agonist can activate PP2A, leading to the dephos-
phorylation of Rb and the inhibition of cancer cell proliferation
(Srivastava et al., 2014). We postulate that the same effect on
Rb might also happen as a result of MCB-613-mediated eleva-
tion of ROS levels and contribute to the final deleterious effect of
MCB-613 on cancer cells, although not necessarily as a direct
consequence of SRC hyper-activation.
Because neither Abl kinase inhibitors nor siRNA-mediated
Abl knockdown can completely block the activation of SRCsIND-SRC-3 and treated with MCB-613 for 24 hr in the presence or absence of
pBIND or pBIND-SRC-3 and pG5-luc, followed by treatment with increasing
ciency of Abl is shown at the right.
Figure S4.
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Figure 6. Mechanistic Model of SRC Hyper-activation by MCB-613
By directly binding to SRCs, MCB-613 increases the interaction between
SRCs and other coactivators such as CBP and CARM1. Meanwhile, the
resultant elevated ROS activates Abl kinase, which phosphorylates and further
hyper-activates SRCs. The deregulation of cellular functions and homeostasis
downstream of SRCs hyper-activation strongly induces ER stress and UPR,
producing more ROS and forming a positive feedback loop. The resultant
excessive ER and oxidative stress overwhelms cancer cells, leading to
vacuolization and cell death.by MCB-613, we believe that Abl may not be the sole stress-
related kinase or factor involved in SRC hyper-activation
and that the actions of MCB-613 extend beyond the activation
of Abl. Studies using SRC-3 phosphomutants led us to the
conclusion that MCB-613 treatment probably leads to a
distinct phosphorylation pattern on SRC-3. Although we have
focused on phosphorylation, we have not ruled out the possibil-
ity that MCB-613 might induce other post-translational modifi-
cations on SRCs, which will be interesting to pursue in future
studies.
We noted that MCB-613 is part of the chalcone class of
compounds. Chalcones are widely produced in plants as
intermediates in the biosynthesis of flavonoids. The common
1,3-diphenyl propenone template of these compounds allows
for easy chemical modification, which results in significant
and distinct alterations in their molecular targets and biological
functions. Various molecular targets of chalcones have been
reported, including epidermal growth factor receptor (EGFR),
tubulin, NRF2, nuclear factor kB (NF-kB), and others, many
of which are critical players in carcinogenesis (Karthikeyan
et al., 2015). Therefore, the anti-cancer activity of chalcones
has been the subject of intensive research and represents
a promising class of compounds for therapeutic development.
This study establishes the major biological activity of MCB-250 Cancer Cell 28, 240–252, August 10, 2015 ª2015 Elsevier Inc.613 as a compound that can induce catastrophic stress
and death in cancer cells primarily by targeting SRC family
proteins.
The selective cancer cell cytotoxicity of MCB-613 is similar
to that seen with another small molecule compound, piperlongu-
mine, that was identified from a high-throughput chemical
screen for compounds able to exacerbate cellular stressors
that are already fully engaged in cancer cells (Raj et al., 2011).
This initial study has led to the development of piperlongumine
derivatives with improved drug-like properties (Adams et al.,
2013). Although these compounds are thought to target
enzymes involved in redox maintenance, such as glutathione
synthetase and glutathionylation (Adams et al., 2012), MCB-
613 can be distinguished by the fact that it functions by selec-
tively targeting and stimulating a family of oncogenes.
Virtually all targeted therapies for key cancer oncogenes are
designed to inhibit their activities. Here we argue that, although
seemingly counterintuitive, oncogene hyper-stimulation war-
rants consideration as well. Some evidence that supports this
idea comes from studies where oncogene activation in an
inappropriate context can inhibit cancer growth. For instance,
induction of oncogenic Ras in glioblastomas and gastric cancers
is very rare, and its experimental activation in the cell culture
models of these cancer types can lead to cell death (Chi et al.,
1999). Just as we have found through our re-analysis of high-
throughput screens originally designed to identify SRC SMIs,
an opportunity to re-evaluate compounds identified as onco-
gene activators in other screens also exists. Based on our char-
acterization of MCB-613, we anticipate that, in the future, other
SMSs that target oncogenes can be exploited as anti-cancer
agents as well.EXPERIMENTAL PROCEDURES
More procedures can be found in the Supplemental Experimental Procedures.High-Throughput Chemical Screens
A Molecular Libraries Small Molecule Repository (MLSMR) library was pro-
vided by Evotec through the NIH’s Roadmap Molecular Libraries Initiative
for the high-throughput screening for SRC-1/2/3 inhibitors. Details about
compound selection for this library can be found at http://mli.nih.gov/mli/
compound-repository/mlsmr-compounds/.MCF-7 Xenograft Tumor Model
Animal work was done in accordance with a protocol approved by the Animal
Care andUseCommittee of Baylor College ofMedicine. 6- to 8-week-old athy-
mic nude female mice were obtained from Harlan. Two days before cancer cell
injection, one estradiol pellet was embedded under the skin for each mouse,
and a new pellet was added two times at a 1-month interval. 13 106 MCF-7
cells (50 ml) mixed with an equal volume of growth factor-reduced Matrigel
(BD Biosciences) were injected into the fat pads of each of the second-pair
mammary gland without clearing. The MCB-613 treatment, which lasted for
7 weeks, was started when tumor sizes reached 3–5 mm in diameter. Mice
of the treatment group (n = 13) received MCB-613 (20 mg/kg) in saline by
i.p. injection, whereas the control group (n = 14) received saline only. The com-
pound was injected three times a week. The mice were weighed, and tumors
were measured once a week during the treatment period.Statistics
Statistical significancewas determined by two-tailed Student’s t test. A p value
of less than 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.07.005.
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